A framework for identifying targets for individualized therapy in genetic disease

DOI: https://doi.org/10.1038/d41586-023-01994-y
IF: 64.8
2023-07-13
Nature
Abstract:Researchers have developed a system to classify genetic mutations that could be addressed by therapeutic interventions that use 'splice-switching antisense oligonucleotides'. This framework identified multiple eligible mutations among 235 people with the genetic disorder ataxia–telangiectasia. An oligonucleotide that was specific to one of these mutations was advanced to a proof-of-concept individualized trial. Genetic variants that cause a rare neurological disorder have been classified according to their amenability to treatment.
multidisciplinary sciences
What problem does this paper attempt to address?